These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 37021053)

  • 1. Therapeutic implications of current Janus kinase inhibitors as anti-COVID agents: A review.
    Jain NK; Tailang M; Jain HK; Chandrasekaran B; Sahoo BM; Subramanian A; Thangavel N; Aldahish A; Chidambaram K; Alagusundaram M; Kumar S; Selvam P
    Front Pharmacol; 2023; 14():1135145. PubMed ID: 37021053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hi-
    Burja B; Mertelj T; Frank-Bertoncelj M
    Front Med (Lausanne); 2020; 7():124. PubMed ID: 32432116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Jakinibs of All Trades: Inhibiting Cytokine Signaling in Immune-Mediated Pathologies.
    Alexander M; Luo Y; Raimondi G; O'Shea JJ; Gadina M
    Pharmaceuticals (Basel); 2021 Dec; 15(1):. PubMed ID: 35056105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Janus kinase inhibitors for rheumatoid arthritis.
    Yamaoka K
    Curr Opin Chem Biol; 2016 Jun; 32():29-33. PubMed ID: 26994322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JAK inhibitors: Ten years after.
    Spinelli FR; Meylan F; O'Shea JJ; Gadina M
    Eur J Immunol; 2021 Jul; 51(7):1615-1627. PubMed ID: 33930196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in JAK Isoform Selectivity Among Different Types of JAK Inhibitors Evaluated for Rheumatic Diseases Through In Vitro Profiling.
    Virtanen A; Palmroth M; Liukkonen S; Kurttila A; Haikarainen T; Isomäki P; Silvennoinen O
    Arthritis Rheumatol; 2023 Nov; 75(11):2054-2061. PubMed ID: 37134144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JAK-STAT inhibitors for the treatment of immunomediated diseases.
    Serra López-Matencio JM; Morell Baladrón A; Castañeda S
    Med Clin (Barc); 2019 May; 152(9):353-360. PubMed ID: 30527218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JAK Inhibition as a New Treatment Strategy for Patients with COVID-19.
    Seif F; Aazami H; Khoshmirsafa M; Kamali M; Mohsenzadegan M; Pornour M; Mansouri D
    Int Arch Allergy Immunol; 2020; 181(6):467-475. PubMed ID: 32392562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Jakinibs in systemic lupus erythematosus: progress and prospects.
    Mok CC
    Expert Opin Investig Drugs; 2019 Jan; 28(1):85-92. PubMed ID: 30462559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.
    Zhang X; Zhang Y; Qiao W; Zhang J; Qi Z
    Int Immunopharmacol; 2020 Sep; 86():106749. PubMed ID: 32645632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Janus Kinase Inhibition on the Treatment of Axial Spondyloarthropathies.
    Hammitzsch A; Lorenz G; Moog P
    Front Immunol; 2020; 11():591176. PubMed ID: 33193430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JAK inhibition as a new treatment strategy for patients with COVID-19.
    Huang J; Zhou C; Deng J; Zhou J
    Biochem Pharmacol; 2022 Aug; 202():115162. PubMed ID: 35787993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors-A Strategy for Hematological Malignancies?
    Klein K; Stoiber D; Sexl V; Witalisz-Siepracka A
    Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34073410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Affecting the effectors: JAK inhibitors modulation of immune cell numbers and functions in patients with rheumatoid arthritis.
    Garufi C; Maclean M; Gadina M; Spinelli FR
    Expert Rev Clin Immunol; 2022 Mar; 18(3):309-319. PubMed ID: 35168456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 and the potential of Janus family kinase (JAK) pathway inhibition: A novel treatment strategy.
    Khaledi M; Sameni F; Yahyazade S; Radandish M; Owlia P; Bagheri N; Afkhami H; Mahjoor M; Esmaelpour Z; Kohansal M; Aghaei F
    Front Med (Lausanne); 2022; 9():961027. PubMed ID: 36111104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story.
    Bonelli M; Kerschbaumer A; Kastrati K; Ghoreschi K; Gadina M; Heinz LX; Smolen JS; Aletaha D; O'Shea J; Laurence A
    Ann Rheum Dis; 2024 Jan; 83(2):139-160. PubMed ID: 37923366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic potential of JAK/STAT pathway modulation in mood disorders.
    Shariq AS; Brietzke E; Rosenblat JD; Pan Z; Rong C; Ragguett RM; Park C; McIntyre RS
    Rev Neurosci; 2018 Dec; 30(1):1-7. PubMed ID: 29902157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.
    Traves PG; Murray B; Campigotto F; Galien R; Meng A; Di Paolo JA
    Ann Rheum Dis; 2021 Jul; 80(7):865-875. PubMed ID: 33741556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Decade of JAK Inhibitors: What Have We Learned and What May Be the Future?
    Liu C; Kieltyka J; Fleischmann R; Gadina M; O'Shea JJ
    Arthritis Rheumatol; 2021 Dec; 73(12):2166-2178. PubMed ID: 34180156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.